External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.

ABSTRACT:

Importance

Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined.

Objective

To assess whether the prognostic ability of the clinical score (CS) could be validated in an external cohort of patients with WD NETs.

Design, setting, and participants

This multicenter cohort study's analysis included patients with WD NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-dotatate between March 1, 2016, and March 17, 2020. The original cohort included patients from Vanderbilt-Ingram Cancer Center. The validation cohort included pat

SUBMITTER: Das S 

PROVIDER: S-EPMC8771294 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature